IDO1 and melanoma: BMS-986205 is an orally administered, irreversible IDO1 inhibitor, which binds to the apo-IDO1 protein lacking haem.1,21,22 Bristol-Myers Squib evaluated the therapeutic efficacy of BMS-986205 in combination with nivolumab, another anti-PD-1 antibody, in several advanced cancers (NCT02658890), metastatic or non-resectable melanoma patients (NCT03329846), NSCLC (NCT03417037) and head and neck cancer (NCT03386838).